Home / Health / Xanax Recall: Critical Dissolution Failure
Xanax Recall: Critical Dissolution Failure
15 Apr
Summary
- A specific lot of Xanax XR 3mg tablets recalled.
- Recall due to failure in dissolution quality control tests.
- FDA classified the event as a Class II recall.

A nationwide recall has been issued for a specific lot of Xanax XR, the popular medication for anxiety and panic disorders. The recall, initiated by pharmaceutical company Viatris Inc., affects lot #8177156 of the 3mg extended-release tablets in 60-tablet bottles, which expire on February 28, 2027.
The U.S. Food and Drug Administration (FDA) has classified this recall as Class II. This designation indicates that exposure to the recalled product may cause temporary or medically reversible adverse health effects. The primary reason for the recall is the drug's failure to meet dissolution specifications during quality control testing.